Back to Search
Start Over
Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.
- Source :
-
International journal of antimicrobial agents [Int J Antimicrob Agents] 2014 Jul; Vol. 44 (1), pp. 56-64. Date of Electronic Publication: 2014 May 16. - Publication Year :
- 2014
-
Abstract
- This retrospective observational medical chart review aimed to describe country-specific variations across Europe in real-world meticillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infection (cSSTI) treatment patterns, antibiotic stewardship activity, and potential opportunities for early switch (ES) from intravenous (i.v.) to oral formulations and early discharge (ED) from hospital using standardised data collection and criteria and economic implications of these opportunities. Patients were randomly sampled from 12 countries (Austria, Czech Republic, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Slovakia, Spain and the UK), aged ≥18 years, with documented MRSA cSSTI, hospitalised between 1 July 2010 and 30 June 2011, discharged alive by 31 July 2011. Of 1502 patients, 1468 received MRSA-targeted therapy. Intravenous-to-oral switch rates ranged from 2.0% to 20.2%, i.v. length of therapy from 10.1 to 18.6 days and hospital length of stay (LoS) from 15.2 to 25.0 days across Europe. Of 341 sites, 82.9% had antibiotic steering committees, 23.7% had i.v.-to-oral switch antibiotic protocols and 12.9% had ED protocols for MRSA cSSTI. ES and ED eligibility ranged from 12.0% (Slovakia) to 56.3% (Greece) and from 10% (Slovakia) to 48.2% (Portugal), respectively. Potential cost savings per ED-eligible patient ranged from €414 (Slovakia) to €2703 (France). MRSA cSSTI treatment patterns varied widely across countries, but further reductions in i.v. therapy, hospital LoS and associated costs could be realised. These data provide insight into clinical practice patterns across diverse European healthcare systems and identify potential opportunities for local clinicians and policy-makers to improve clinical care and cost-effectiveness of this therapeutic area.<br /> (Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Acetamides economics
Administration, Oral
Adult
Aged
Anti-Bacterial Agents economics
Drug Administration Schedule
Europe
Female
Hospitalization economics
Hospitalization statistics & numerical data
Humans
Injections, Intravenous
Length of Stay economics
Length of Stay statistics & numerical data
Linezolid
Male
Methicillin-Resistant Staphylococcus aureus growth & development
Middle Aged
Oxazolidinones economics
Patient Discharge
Practice Guidelines as Topic
Retrospective Studies
Soft Tissue Infections economics
Soft Tissue Infections microbiology
Soft Tissue Infections pathology
Staphylococcal Skin Infections economics
Staphylococcal Skin Infections microbiology
Staphylococcal Skin Infections pathology
Vancomycin economics
Acetamides therapeutic use
Anti-Bacterial Agents therapeutic use
Methicillin-Resistant Staphylococcus aureus drug effects
Oxazolidinones therapeutic use
Soft Tissue Infections drug therapy
Staphylococcal Skin Infections drug therapy
Vancomycin therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1872-7913
- Volume :
- 44
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- International journal of antimicrobial agents
- Publication Type :
- Academic Journal
- Accession number :
- 24928311
- Full Text :
- https://doi.org/10.1016/j.ijantimicag.2014.04.007